HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Veterinary Medicines
  • >CMDv
  • >Procedural guidance
  • >Post Marketing Procedures
  • >Pharmacovigilance
  • CMDv
    • About CMDv
    • Implementation of the VMP Regulation
    • BREXIT
    • Advice from CMDv
    • Procedural Contact Points
    • Procedural guidance
      • General Information on Applications
      • Validation of Applications
      • Applications for Marketing Authorisation
      • Post Marketing Procedures
        • Variations
        • Pharmacovigilance
      • CMDv Review Procedure and Referrals
      • Re-examination after DCP/VRA
      • Parallel trade
      • SPC Harmonisation
      • ASMF
      • SPC, Labelling and Package leaflet
      • Borderline products
      • Clinical trials
      • Miscellaneous
    • Questions & Answers
    • Publications
    • Union Product Database (UPD)
  • VMRI Product Index
  • National Contacts

 

Pharmacovigilance

Guidance documents on pharmacovigilance - Regulation (EU) 2019/6

Q&A on transitional arrangements from Directive 2001/82 to Regulation (EU) 2019/6

 

Best practice guide

Best practice guide for the CMDv tasks related to pharmacovigilance

Further guidance on pharmacovigilance and signal detection (EMA website)

 

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/veterinary-medicines/cmdv/procedural-guidance/post-marketing-procedures/pharmacovigilance.html